ReviewPharmaceuticals (Basel, Switzerland)2023
An Update on the Therapeutic Potential of Antimicrobial Peptides against
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Therapeutic efficacy and mechanisms of Xuebijing inFrontiers in pharmacology · 2025Pooled it
- Computational screening of antimicrobial peptide analogs targeting AdeB efflux transporter protein in Acinetobacter baumannii associated with multidrug resistance.Scientific reports · 2026Article
- In Silico Identification and Molecular Characterization ofAntibiotics (Basel, Switzerland) · 2025Article
- Bicarinalin Enhances the Antibacterial Activity of Levofloxacin and Clarithromycin AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Diagnostic and therapeutic strategies in combating implanted medical device-associated bacterial biofilm infections.Folia microbiologica · 2025Review
- New Antimicrobial Cyclodepsipeptides from a Freshwater Fungus from the Sierra Madre Oriental in Mexico.ACS omega · 2025Article
- Review
- Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer AgainstAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Review
- Effect of Camel Peptide on the Biofilm ofAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The rise in antibiotic-resistant strains of clinically important pathogens is a major threat to global health. The World Health Organization (WHO) has recognized the urgent need to develop alternative treatments to address the growing list of priority pathogens. Antimicrobial peptides (AMPs) rank among the suggested options with proven activity and high potential to be developed into effective drugs. Many AMPs are naturally produced by living organisms protecting the host against pathogens as a part of their innate immunity. Mechanisms associated with AMP actions include cell membrane disruption, cell wall weakening, protein synthesis inhibition, and interference in nucleic acid dynamics, inducing apoptosis and necrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.